HCWB HCW Biologics Inc.

Subscribe to $HCWB

HCW Biologics Inc.

Subscribe to $HCWB

$HCWB

Biotechnology: Pharmaceutical Preparations

Health Care

IPO Year: 2021

Exchange: NASDAQ

Recent Analyst Ratings for HCW Biologics Inc.

Date	Price Target	Rating	Analyst
11/19/2021	$10.00	Buy	EF Hutton

See more ratings

HCW Biologics Inc. Press Releases

Fastest customizable press release news feed in the world

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated Presentation at the Phoenix Best Science Series by HonorHealth Research Instituteon June 27, 2025 in Scottsdale, Arizona MIRAMAR, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have success
6/27/25 7:45:56 AM ET
$HCWB
Biotechnology: Pharmaceutical Preparations
Health Care
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). On June 24, 2025, HCWB received formal notice from Nasdaq confirming that the Company has satisfied
6/26/25 7:55:49 AM ET
$HCWB
Biotechnology: Pharmaceutical Preparations
Health Care
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that WY Biotech has completed its due diligence related to HCWB's technology transfer report, including the characterization of the cell line, delivered on May 13, 2025. In addition, WY Biotech confirmed its commitmen
6/4/25 8:20:19 AM ET
$HCWB
Biotechnology: Pharmaceutical Preparations
Health Care
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2025. On May 15, 2025, the Company closed an equity offering with gross proceeds of $5.0 million with a single institutional investor. Dr. Hing Wong, Founder and CEO, stated, "We are pleased to have completed a successful $5.0 million equity offering in a difficult market without
5/15/25 6:14:42 PM ET
$HCWB
Biotechnology: Pharmaceutical Preparations
Health Care
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced the pricing of its follow-on offering of an aggregate of 671,140 units at a purchase price of $7.45 per unit priced at-the-market under Nasdaq rules. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and two warrants, each to purchase one share of common stock. The warrants will have an exercise price of $7.45 per share, will be exercisable immed
5/13/25 8:01:40 PM ET
$HCWB
Biotechnology: Pharmaceutical Preparations
Health Care
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells Data Shared at 2025 Annual Meeting of American Association of Immunologists MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today presentation of studies showing that its proprietary fusion protein, HCW9206, provides a new pathway for generating chimeric T-cell receptor - T
5/13/25 8:30:20 AM ET
$HCWB
Biotechnology: Pharmaceutical Preparations
Health Care
HCW Biologics Announces 1-for-40 Reverse Stock Split
MIRAMAR, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that its Board of Directors has approved a 1-for-40 reverse stock split of the Company's common stock, par value $0.0001 ("Common Stock"), which will be effective at 12:01 a.m. Eastern Time on April 11, 2025. The Company's Common Stock will be traded on The Nasdaq Capital Market on a reverse split-adjusted basis beginning on April 11, 2025, under the Company's exi
4/1/25 4:35:03 PM ET
$HCWB
Biotechnology: Pharmaceutical Preparations
Health Care
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
MIRAMAR, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2024. Dr. Hing Wong, Founder and CEO, stated, "We are more passionate than ever about our desire to create breakthrough immunotherapeutic treatments for diseases with no known cures, especially pancreatic, ovarian cancer and other age-related diseases. We h
3/28/25 3:30:17 PM ET
$HCWB
Biotechnology: Pharmaceutical Preparations
Health Care
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
MIRAMAR, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported that, on March 3, 2025, the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq" or the "Exchange") granted the Company an extension in which to regain compliance with all continued listing rules of The Nasdaq Capital Market. The Panel's determination follows a hearing on February 13, 2025, at which the Panel considered the Company's plan to
3/6/25 6:55:18 AM ET
$HCWB
Biotechnology: Pharmaceutical Preparations
Health Care
HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
MIRAMAR, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, today announced that it has received clearance of its Investigational New Drug Application ("IND") from the U.S. Food and Drug Administration ("FDA") to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in patients with moderate-to-severe alopecia areata, a common autoimmune disease in humans that currently has no
2/3/25 7:15:07 AM ET
$HCWB
Biotechnology: Pharmaceutical Preparations
Health Care

HCW Biologics Inc.

Recent Analyst Ratings for HCW Biologics Inc.

HCW Biologics Inc. Press Releases

Fastest customizable press release news feed in the world

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

HCW Biologics Announces 1-for-40 Reverse Stock Split

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

HCW Biologics Inc. SEC Filings

HCW Biologics Inc. filed SEC Form 8-K: Other Events

HCW Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

HCW Biologics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

HCW Biologics Inc. filed SEC Form 8-K: Other Events

HCW Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

HCW Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

HCW Biologics Inc. filed SEC Form 8-K: Other Events

HCW Biologics Inc. filed SEC Form 8-K: Other Events

HCW Biologics Inc. filed SEC Form 8-K: Other Events

SEC Form 10-Q filed by HCW Biologics Inc.

HCW Biologics Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

Director Winer Gary M bought $60,008 worth of shares (2,308 units at $26.00), increasing direct ownership by 543% to 2,733 units (SEC Form 4)

Chief Executive Officer Wong Hing C bought $2,405,000 worth of shares (92,500 units at $26.00), increasing direct ownership by 23% to 493,857 units (SEC Form 4)

Director Garrett Scott T bought $140,010 worth of shares (5,385 units at $26.00), increasing direct ownership by 80% to 12,082 units (SEC Form 4)

Chief Financial Officer Byam Rebecca bought $220,012 worth of shares (8,462 units at $26.00), increasing direct ownership by 24% to 43,010 units (SEC Form 4)

SVP of Business Development Flowers Lee bought $25,012 worth of shares (962 units at $26.00), increasing direct ownership by 20% to 5,720 units (SEC Form 4)

Director Greene Rick S. bought $25,012 worth of shares (962 units at $26.00), increasing direct ownership by 87% to 2,066 units (SEC Form 4)

SEC Form 4: Wong Hing C bought $3,741 worth of shares (1,800 units at $2.08), increasing direct ownership by 0.01% to 15,314,868 units

HCW Biologics Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

EF Hutton initiated coverage on HCW Biologics with a new price target

HCW Biologics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

Director Winer Gary M bought $60,008 worth of shares (2,308 units at $26.00), increasing direct ownership by 543% to 2,733 units (SEC Form 4)

Chief Executive Officer Wong Hing C bought $2,405,000 worth of shares (92,500 units at $26.00), increasing direct ownership by 23% to 493,857 units (SEC Form 4)

Director Garrett Scott T bought $140,010 worth of shares (5,385 units at $26.00), increasing direct ownership by 80% to 12,082 units (SEC Form 4)

Chief Financial Officer Byam Rebecca bought $220,012 worth of shares (8,462 units at $26.00), increasing direct ownership by 24% to 43,010 units (SEC Form 4)

SVP of Business Development Flowers Lee bought $25,012 worth of shares (962 units at $26.00), increasing direct ownership by 20% to 5,720 units (SEC Form 4)

Director Greene Rick S. bought $25,012 worth of shares (962 units at $26.00), increasing direct ownership by 87% to 2,066 units (SEC Form 4)

SEC Form 4 filed by Director Giles Lisa M.

HCW Biologics Inc. Financials

Live finance-specific insights

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights